Previous 10 | Next 10 |
Life Science Company Live Investor Conference July 11th Canada NewsWire NEW YORK, July 9, 2019 Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /CNW/ - Virtual Investor Conference...
Menlo Therapeutics ( MNLO ) was founded in 2011 and is focused on tackling pruritus associated conditions. The company came to public early this year. The company's headquarters are based in Redwood City, California, and its main focus is on advancing their lead product candidate, serlopitant,...
REDWOOD CITY, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at th...
Menlo Therapeutics (NASDAQ: MNLO ): Q1 GAAP EPS of -$0.81 misses by $0.01 . More news on: Menlo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
REDWOOD CITY, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the first quarter ended March 31, 2019 ...
Quick Take Trevi Therapeutics ( TRVI ) intends to raise $70.0 million from the sale of common stock in an IPO, per an amended registration statement . The company is advancing a series of treatment programs for various conditions that may be treated by its nalbuphine ER compound. TRVI h...
REDWOOD CITY, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at ...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year tests of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio...
REDWOOD CITY, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of se...
REDWOOD CITY, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has been appointed as a member of M...
News, Short Squeeze, Breakout and More Instantly...
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Confe...
BRIDGEWATER, N.J. , Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "...
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”...